Alemtuzumab
Alemtuzumab
Definition
A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04)
Also known as ALEMTUZUMAB, Campath, Campath-1H, LDP 03, LDP-03, LDP03, Lemtrada, MabCampath — per NCIT
Also identified as
- ATC L04AG06 per RXNORM
- NCIT NCIT:C1681 per NCIT
- SCTID 129472003 per RXNORM
- SCTID 391632007 per RXNORM
- UNII 3A189DH42V per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| B-cell chronic lymphocytic leukemia | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Bone marrow | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Lymphoid system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
2 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.